Citius Oncology, Inc.
CTOR
$1.22
-$0.08-6.15%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.51% | -15.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.81% | 16.83% | |||
| Operating Income | 33.81% | -16.83% | |||
| Income Before Tax | 31.66% | -16.83% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | 30.58% | -16.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.58% | -16.16% | |||
| EBIT | 33.81% | -16.83% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 30.62% | -16.11% | |||
| Normalized Basic EPS | 31.70% | -16.82% | |||
| EPS Diluted | 30.62% | -16.11% | |||
| Normalized Diluted EPS | 31.70% | -16.82% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||